ENABLEX
What it isM3-selective muscarinic antagonist; urgency and urge incontinence from overactive bladder.
Why this oneIts bladder-focused M3 selectivity aims to spare cognitive M1 effects better than oxybutynin.
What limits itConstipation and dry mouth remain prominent; urinary retention and CYP2D6 or CYP3A4 interactions can end treatment.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Overactive bladder (urge incontinence, urgency, frequency) | Adults | 7.5 mg QD | 7.5-15 mg QD | 15 mg QD |
Titration May increase to 15 mg QD as early as 2 weeks after starting.
Renal Undefined
Hepatic Moderate (Child-Pugh B): do not exceed 7.5 mg QD. Severe (Child-Pugh C): not recommended.
Pregnancy No human data; not teratogenic in animals. Use only if benefit outweighs fetal risk.
Lactation No human data; present in rat milk.
NO BOXED WARNINGS
Principal riskConstipation and dry mouth
Cost, est. cash$10–$300/month
Generic entry2015
Legacy pregnancy categoryC
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Open Darifenacin in the interactive console ↗

